Related Experiment Video

Updated: Aug 14, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors

Z Fishelson1, N Donin, S Zell

  • 1Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel. lifish@post.tau.ac.il

Molecular Immunology
|August 14, 2003
PubMed

Insights

Cancer cells resist antibody therapy by expressing membrane complement regulatory proteins (mCRPs). Blocking these proteins, like CD59, enhances antibody effectiveness against tumors, improving cancer treatment outcomes.

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Monoclonal antibodies (mAbs) are vital in cancer therapy, targeting cancer cells to induce cell death.
  • Cancer cells employ resistance mechanisms, notably expressing membrane complement regulatory proteins (mCRPs), to evade antibody-mediated killing.
  • mCRPs such as CD46, CD55, CD35, and CD59 protect cells from complement system damage, but also shield tumors from therapeutic antibodies.

Purpose of the Study:

  • To investigate the role of mCRPs in cancer cell resistance to complement-dependent cytotoxicity induced by therapeutic antibodies.
  • To evaluate the potential of targeting mCRPs to enhance the efficacy of antibody-based cancer therapies.

Main Methods:

  • In vitro studies using neutralizing anti-mCRP monoclonal antibodies (mAbs).
  • Analysis of mCRP expression levels in various tumor types and their correlation with complement resistance.
  • Assessment of the combined effects of anti-mCRP mAbs and complement-fixing anticancer mAbs.

Main Results:

  • Cancer cells express varying levels of mCRPs, with some tumors showing higher expression than normal tissues.
  • CD59 was identified as a key mCRP conferring resistance to complement-mediated lysis, often acting additively or synergistically with CD46 and CD55.
  • Neutralizing anti-mCRP mAbs demonstrated the significance of mCRP expression in tumor resistance phenotypes.

Conclusions:

  • mCRPs are critical for cancer cell survival against complement-mediated attack.
  • Targeting mCRPs, particularly CD59, in combination with complement-fixing anticancer mAbs holds promise for improving therapeutic outcomes in cancer patients.
  • Further research into mCRP expression patterns and targeted inhibition strategies is warranted for optimized cancer immunotherapy.

More Related Videos

Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion06:54

Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion

Published on: June 15, 2019

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.